RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Status:
Completed
Trial end date:
2016-11-07
Target enrollment:
Participant gender:
Summary
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line
treatment of patients with metastatic papillary carcinoma of the kidney.